Diabetes drugs and weight loss - Mayo Clinic
2024年11月14日 · Tirzepatide (Mounjaro) is a similar kind of medicine called a dual-acting GLP-1/GIP agonist. It's also used to control blood sugar and can support weight loss. It is taken once a week by a shot. All GLP-1 agonists can help with weight loss. But the amount of weight loss depends on the type of medicine and the dose.
ناهضات GLP-1: عقاقير مرض السكري وفقدان الوزن - Mayo Clinic (مايو كلينك)
Hu M, et al. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: A meta-analysis.
Semaglutide (subcutaneous route) - Mayo Clinic
2024年10月1日 · Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide injection is also used together with diet and exercise to help lose weight and keep the weight off in patients with at least one weight-related medical condition. This medicine is available only with your doctor's prescription.
Agonistas del GLP-1: fármacos para la diabetes y pérdida de peso
2022年8月11日 · Los niveles más bajos de glucosa en la sangre son útiles para controlar la diabetes tipo 2, pero no se sabe exactamente cómo los medicamentos de péptido similar al glucagón tipo 1 conducen a la pérdida de peso. Los médicos saben que los péptidos similares al glucagón tipo 1 parecen ayudar a controlar el hambre. Estos medicamentos ...
Use of weight-loss pharmacotherapy in patients with cirrhosis and …
2021年8月17日 · The four weight-loss medications currently approved by the FDA for treatment of obesity are orlistat, phentermine-topiramate, naltrexone-bupropion and liraglutide. Although some society guidelines have endorsed the use of these medications in patients with cirrhosis or in liver transplant recipients, they have not yet been widely used in this ...
Why gastroenterologists and hepatologists should be involved in ...
2023年6月16日 · A dual incretin agonist (GLP-1/glucose-dependent insulinotropic peptide) tirzepatide also is efficacious in treating obesity, improving glycemic control and reducing liver fat content. Researchers have demonstrated the ability of other dual incretin agonists, such as cotadutide and pemvidutide, to reduce significant hepatic fibrosis in both ...
Management of obesity within hepatology clinics - Mayo Clinic
2023年12月12日 · Glucagon-like peptide 1 (GLP-1) receptor agonists. These agents can lead to significant weight loss. According to Dr. Watt, developing a solid understanding of how the various GLP-1 receptor agonists differ from one another may help clinicians choose the most appropriate agent for an individual patient. The Hepatology article contains a ...
Tirzepatide (subcutaneous route) - Mayo Clinic
2024年4月1日 · It is used together with diet and exercise to help control your blood sugar. Tirzapatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions.
Liraglutide (subcutaneous route) - Mayo Clinic
2024年10月1日 · This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide injection is also used together with a reduced-calorie diet and proper exercise to help patients with obesity lose weight. This medicine is available only with your doctor's prescription.
Semaglutide (oral route) - Mayo Clinic
Semaglutide is used to treat type 2 diabetes. It is used together with diet and exercise to help control your blood sugar. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. This medicine is available only with your doctor's prescription.